SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
PURSUANT TO SECTION 13 OR 15(C) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of the Earliest Event Reported) November 13, 2003
Valeant Pharmaceuticals
International
(Exact name of
registrant as specified in its charter)
| Delaware | 1-11397 | 33-0628076 | ||
| (State or other jurisdiction
of incorporation or organization) |
(Commission file number) |
(I.R.S. Employer Identification No.) |
3300 Hyland Avenue
Costa Mesa, California
92626
(Address of principal executive offices)(Zip code)
(714) 545-0100
(Registrant’s
telephone
number, including area code)
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
(c) Exhibits
| Exhibit No. | Description | |||
| 99.1 | Excerpts from Confidential Offering Circular | |||
Item 9. Regulation FD Disclosure
On November 13, 2003, Valeant Pharmaceuticals International announced that it intends to offer, subject to market and other conditions, convertible subordinated notes (the “Notes”) in a transaction exempt from the registration requirements of the Securities Act of 1933. Attached hereto as Exhibit 99.1 are excerpts from the Confidential Offering Circular relating to the Notes.
Pursuant to the requirements of the Securities Exchange Act of 1934, Valeant Pharmaceuticals International has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: November 13, 2003 | VALEANT PHARMACEUTICALS INTERNATIONAL |
| /s/ Bary G. Bailey |
|
| Executive Vice President and Chief Financial Officer |
| Designation | Description | |||
| 99.1 | Excerpts from Confidential Offering Circular | |||